Gefitinib Combined With Thalidomide to Treat NSCLC

Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)

NCT02338011 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

NCT02824458 ·Status: UNKNOWN ·Phase: PHASE3

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

NCT03267654 ·Status: UNKNOWN ·Phase: PHASE2

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

NCT02930954 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test

NCT02738684 ·Status: UNKNOWN

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

NCT02088112 ·Status: COMPLETED ·Phase: PHASE1

NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.

NCT02347839 ·Status: WITHDRAWN ·Phase: PHASE2

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

NCT02098954 ·Status: RECRUITING ·Phase: PHASE2

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT00536107 ·Status: TERMINATED ·Phase: PHASE4

Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)

NCT00452244 ·Status: COMPLETED ·Phase: PHASE2

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

NCT02299765 ·Status: TERMINATED ·Phase: PHASE4

Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation

NCT01405079 ·Status: UNKNOWN ·Phase: PHASE3

Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)

NCT01147211 ·Status: UNKNOWN ·Phase: PHASE1

A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT04239833 ·Status: UNKNOWN ·Phase: PHASE3

Combination of Chemotherapy and Gefitinib as First-line Treatment

NCT02148380 ·Status: COMPLETED ·Phase: NA

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

NCT02906163 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB

NCT02326285 ·Status: TERMINATED ·Phase: PHASE2/PHASE3

Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC

NCT02353741 ·Status: TERMINATED ·Phase: PHASE2

Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC

NCT01755923 ·Status: UNKNOWN ·Phase: PHASE2

Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer

NCT01407822 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Selumetinib in Combination With Gefitinib in NSCLC Patients

NCT02025114 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

NCT01469000 ·Status: COMPLETED ·Phase: PHASE2

Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

NCT03381430 ·Status: NOT_YET_RECRUITING ·Phase: NA

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

NCT02870569 ·Status: COMPLETED ·Phase: PHASE2

Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

NCT00986284 ·Status: SUSPENDED ·Phase: PHASE2